Editorial Comment to Real‐World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study

Key Points

• To provide an editorial commentary on adverse events associated with pembrolizumab therapy for renal cell carcinoma based on real-world data.
• Multicenter retrospective study
• Focused on adverse event occurrences related to pembrolizumab treatment
• No specific results or data disseminated in the editorial comment.
• Emphasized the need for increased awareness of potential adverse events.